Varenicline
- Generic Name
- Varenicline
- Brand Names
- Champix, Chantix, Tyrvaya
- Drug Type
- Small Molecule
- Chemical Formula
- C13H13N3
- CAS Number
- 249296-44-4
- Unique Ingredient Identifier
- W6HS99O8ZO
- Background
Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A...
- Indication
For use as an aid in smoking cessation.
Varenicline as a nasal spray is indicated for the symptomatic treatment of dry eye disease.
- Associated Conditions
- Dry Eye Syndrome (DES)
- Associated Therapies
- Smoking, Cessation
Endothelial Function and Autonomic Regulation After Short-term Smoking Cessation: Varenicline Versus Placebo
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2012-03-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 19
- Registration Number
- NCT00673595
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Varenicline Observational Investigation In The Cessation of Smoking
- First Posted Date
- 2008-04-30
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 567
- Registration Number
- NCT00669240
- Locations
- 🇸🇮
Pfizer Investigational Site, Maribor, Slovenia
Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity
- Conditions
- Interventions
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2018-05-24
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 140
- Registration Number
- NCT00664755
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
A Study of the Efficacy and Safety of Varenicline in Japanese Smokers Motivated to Quit Smoking
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00635401
- Locations
- 🇯🇵
Pfizer Investigational Site, Oita, Japan
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
- Conditions
- Interventions
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2017-12-21
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 247
- Registration Number
- NCT00621777
- Locations
- 🇺🇸
Centerstone Research Institute, Bloomington, Indiana, United States
🇺🇸University of Minnesota Psychological Clinic, Minneapolis, Minnesota, United States
🇺🇸West Central Behavioral Health, Claremont, New Hampshire, United States
Varenicline and Nicotine Interactions in Humans (VA)
- Conditions
- Interventions
- First Posted Date
- 2008-02-05
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Yale University
- Target Recruit Count
- 37
- Registration Number
- NCT00606892
- Locations
- 🇺🇸
Veterans Affairs Hospital, West Haven, Connecticut, United States
Effects of Varenicline on Brain Activity During Nicotine Abstinence
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 38
- Registration Number
- NCT00602927
- Locations
- 🇺🇸
Tobacco Use Research Center, Philadelphia, Pennsylvania, United States
Efficacy of Varenicline in Ambivalent Smokers
- Conditions
- Interventions
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2011-12-02
- Lead Sponsor
- University of Vermont Medical Center
- Target Recruit Count
- 220
- Registration Number
- NCT00595868
- Locations
- 🇺🇸
University of Vermont, Burlington, Vermont, United States
🇺🇸Nebraska Medical Center, Omaha, Nebraska, United States
Do Treatments for Smoking Cessation Affect Alcohol Drinking?
- First Posted Date
- 2007-12-27
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- Yale University
- Target Recruit Count
- 60
- Registration Number
- NCT00580645
- Locations
- 🇺🇸
Yale Center for Clinical Investigation and Yale Behavioral Pharmacology Laboratory, New Haven, Connecticut, United States
The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior
- Conditions
- Interventions
- First Posted Date
- 2007-12-27
- Last Posted Date
- 2018-02-08
- Lead Sponsor
- Yale University
- Target Recruit Count
- 62
- Registration Number
- NCT00580853
- Locations
- 🇺🇸
Yale Center for Clinical Investigation, Yale University, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.